Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
Zealand Pharma · Short Bowel Syndrome (SBS)
Phase 3
Active, not recruiting
28
2026-07
Evidence dashboardStudies since 2009Updated Jul 31, 2026
GlepaglutideClinical Trials.
A source-linked view of every Glepaglutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 11
- Recruiting
- 1
- Completed
- 7
- Terminated
- 0
- Results posted
- 2
- Average enrollment
- 70
- Countries
- 15
- Highest phase
- Phase 3
Largest indexed study
145 participants · NCT03905707 →Developer / research origin
Zealand Pharma
Evidence summary
Activity is not efficacy.
Glepaglutide appears in 11 indexed studies: 1 recruiting, 7 completed and 2 with registry results posted. The highest registered development stage in this snapshot is Phase 3. These counts measure registry activity; they do not establish that Glepaglutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
Zealand Pharma · Short Bowel Syndrome
Phase 3
Recruiting
90
2026-04
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
Zealand Pharma · Short Bowel Syndrome
Phase 3
Active, not recruiting
129
2026-02
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
Zealand Pharma · Short Bowel Syndrome
Phase 3
Active, not recruiting
145
2026-01
NCT IDStudyPhase / statusEnrollmentUpdated
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
Zealand Pharma · Short Bowel Syndrome
Phase 3
Completed
106
2025-07
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
Zealand Pharma · Short Bowel Syndrome
Phase 3
Completed
12
2024-11
A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.
Zealand Pharma · Healthy
Phase 1
Completed
85
2021-07
Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function
Zealand Pharma · Renal Impairment
Phase 1
Completed
16
2020-11
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
Zealand Pharma · Healthy Subjects
Phase 1
Completed
75
2017-12
A Phase 2 Trial Testing ZP1848 in Patients With SBS
Zealand Pharma · Short Bowel Syndrome
Phase 2
Completed
18
2017-06
Showing 6 of 7 studies
No studies in this snapshot.
Full study index
Search Glepaglutide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
11 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 39708985 ↗Jeppesen PB, Vanuytsel T, Subramanian S, Joly F, Wanten G, Lamprecht G, Kunecki M, Rahman F, Nielsen TSS, Berner-Hansen M, Pape UF, Mercer DF. Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial. Gastroenterology. 2025 Apr;168(4):701-713.e6. doi: 10.1053/j.gastro.2024.11.023. Epub 2024 Dec 19.Linked from NCT03690206PMID 36811175 ↗Agersnap MA, Sonne K, Knudsen KM, Sulowicz W. Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment. Clin Pharmacokinet. 2023 Apr;62(4):645-651. doi: 10.1007/s40262-023-01215-9. Epub 2023 Feb 21.Linked from NCT04178447PMID 36323988 ↗Agersnap MA, Sonne K, Knudsen KM, Knudsen CB, Berner-Hansen M. Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects. Clin Drug Investig. 2022 Dec;42(12):1093-1100. doi: 10.1007/s40261-022-01210-1. Epub 2022 Nov 2.Linked from NCT03279302PMID 34287979 ↗Hvistendahl MK, Naimi RM, Hansen SH, Rehfeld JF, Kissow H, Pedersen J, Dragsted LO, Sonne DP, Knop FK, Jeppesen PB. Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial. JPEN J Parenter Enteral Nutr. 2022 May;46(4):923-935. doi: 10.1002/jpen.2224. Epub 2021 Sep 1.Linked from NCT02690025PMID 31326433 ↗Naimi RM, Hvistendahl M, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Gronbaek H, Moller HJ, Vilstrup H, Steensberg A, Jeppesen PB. Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial. EBioMedicine. 2019 Aug;46:444-451. doi: 10.1016/j.ebiom.2019.07.016. Epub 2019 Jul 17.Linked from NCT02690025PMID 30880176 ↗Naimi RM, Hvistendahl M, Enevoldsen LH, Madsen JL, Fuglsang S, Poulsen SS, Kissow H, Pedersen J, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Holst JJ, Hartmann B, Hansen SH, Dragsted LO, Steensberg A, Mouritzen U, Hansen MB, Jeppesen PB. Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2019 May;4(5):354-363. doi: 10.1016/S2468-1253(19)30077-9. Epub 2019 Mar 15.Linked from NCT02690025
Related pages
Keep researching Glepaglutide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.